Melanoma
Commentary
Discontinuing immunotherapy: Is the infusion bag half empty or half full?
Clinical trials of immunotherapy or chemoimmunotherapy have generally terminated treatment in nonprogressing patients after 2 years.
Conference Coverage
How AI is, or will soon be, relevant in radiation oncology
Radiation oncologists at ASTRO 2022 discuss practical applications of AI, and new research findings.
From the Journals
Chronic stress, especially race related, may hasten cancer death
High allostatic load was associated with an 80% increased risk of cancer death among all study participants.
From the Journals
Third COVID booster benefits cancer patients
For the first time, researchers have quantified the benefits of boosters for COVID-19 in cancer patients.
Latest News
A cost-effective de-escalation strategy in advanced melanoma
While the use of immunotherapies over the past decade has improved the prognosis for patients with advanced melanoma, these drugs come with a...
Latest News
Reminder that COVID-19 and cancer can be a deadly combo
“This analysis provides additional empirical evidence on the magnitude of risk to patients with cancer whose immune systems are often weakened...
Diminutio
Cancer as a full contact sport
The complexity of cancer care has long necessitated a team approach to planning cancer treatment.
From the Journals
Despite benefits, extended-interval pembro uptake remains low
It’s possible that low uptake could stem from clinicians’ doubts about switching to an extended-interval dose, given that the FDA’s approval was...
From the Journals
In stage IIIA melanoma, nodal tumor size could guide decision-making
Sentinel node tumors 3 mm or larger should be considered for adjuvant therapy, while smaller sizes could be treated similarly to AJCC IB.
Conference Coverage
A farewell to arms? Drug approvals based on single-arm trials can be flawed
Objective responses, not time-dependent survival outcomes, should be endpoints for single-arm trials, with results only used for conditional...
Conference Coverage
Time to cancer diagnoses in U.S. averages 5 months
Diagnosis time varied significantly across tumor types, as well as within the same tumor type.